VEGF-Trap Gets Closer to FDA Approval
VEGF-Trap (aka aflibercept), another anti-VEGF drug, moves closer to FDA approval as it received priority review status. This status means that the FDA process will be accelerated and the drug can be reviewed in 6 months versus the usual 10 month period. Alfibercept is another injectable drug that may have an effect on choroidal neovascularization in wet macular degeneration.